ReviewJournal of Zhejiang University. Science. B2014
Harnessing the immune system for the treatment of breast cancer.
Review in Journal of Zhejiang University. Science. B, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context.Frontiers in oncology · 2026Article
- CRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.Journal of Zhejiang University. Science. B · 2023Review
- Molecular interaction of metastasis suppressor genes and tumor microenvironment in breast cancer.Exploration of targeted anti-tumor therapy · 2023Review
- The Innate Immune Microenvironment in Metastatic Breast Cancer.Journal of clinical medicine · 2022Review
- The Role of Extracellular Matrix Proteins in Breast Cancer.Journal of clinical medicine · 2022Review
- Exploring new pathways in endocrine-resistant breast cancer.Exploration of targeted anti-tumor therapy · 2022Review
- Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?Translational oncology · 2021Review
- Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.Oxidative medicine and cellular longevity · 2021Review
- Analysis of theInternational journal of molecular sciences · 2019Article
- Pesticides as the drivers of neuropsychotic diseases, cancers, and teratogenicity among agro-workers as well as general public.Environmental science and pollution research international · 2019Review
- Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.BioMed research international · 2015Review
- Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer.Journal of Zhejiang University. Science. B · 2015Article
- Graft microvascular disease in solid organ transplantation.Journal of molecular medicine (Berlin, Germany) · 2014Review
- Macrophages in solid organ transplantation.Vascular cell · 2014Article
- Green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis.Journal of Zhejiang University. Science. BArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard treatment options for breast cancer include surgery, chemotherapy, radiation, and targeted therapies, such as adjuvant hormonal therapy and monoclonal antibodies. Recently, the recognition that chronic inflammation in the tumor microenvironment promotes tumor growth and survival during different stages of breast cancer development has led to the development of novel immunotherapies. Several immunotherapeutic strategies have been studied both preclinically and clinically and already have been shown to enhance the efficacy of conventional treatment modalities. Therefore, therapies targeting the immune system may represent a promising next-generation approach for the treatment of breast cancers. This review will discuss recent findings that elucidate the roles of suppressive immune cells and proinflammatory cytokines and chemokines in the tumor-promoting microenvironment, and the most current immunotherapeutic strategies in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.